Product Images Sildenafil Citrate

This text appears to be showing the change from baseline measurements in meters for a study conducted over a period of 12 weeks. It mentions different doses of a medication called Sildenafil (20mg, 40mg, and 80mg three times a day) compared to a placebo. The specific details about the study or the context for the measurements are not provided, so further information is not available.*

Table 6 provides hazard ratios for overall survival in the intent-to-treat population, specifically assessing the effects of different doses of Sildenafil (5mg, 20mg, and 80mg). The table includes information on patient-years of follow-up, the number of deaths, and the breakdown of on treatment and off treatment deaths. Hazard ratios relative to the 5mg and 20mg doses of Sildenafil are also provided, along with their corresponding 99.7% confidence intervals. The table also clarifies the definition of on treatment deaths and mentions that hazard ratio estimates were obtained from a proportional hazards model stratified by previous PAH treatment and etiology of PAH.*

Table 7 provides hazard ratios for time to the first event of clinical worsening in the intent-to-treat population. The table includes data on different dosages of sildenafil (5 mg, 20 mg, and 80 mg) and the corresponding number of patients with clinical worsening, including disease progression, hospitalization for pulmonary arterial hypertension (PAH), and death. The hazard ratios are estimated relative to sildenafil 5 mg and sildenafil 20 mg, with corresponding confidence intervals (CI) and p-values. The note indicates that sildenafil 5 mg is not an approved dosage. The table also includes abbreviations and additional information about the definition of clinical worsening events and the methodology used for data analysis.*